Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amer Hawatmeh

Interventional Cardiology Jonesboro, AR Medical Doctor

NPI 1942668082 CMS profile 2781875

201 E Oak Ave, Jonesboro, AR 72401

Open in the dashboard

General payments

$19,518

296 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amer Hawatmeh of Jonesboro, AR is reported in the CMS Open Payments database as having received $19,518 across 296 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,747 50
2024 General $3,934 60
2023 General $2,257 64
2022 General $1,074 33
2021 General $504 22
2020 General $1,970 28
2019 General $8,033 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amer Hawatmeh
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Amer Hawatmeh were reported at $1,747. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Amer Hawatmeh Interventional Cardiology median Middle half National median
2019 $8,033 $1,097 $329–$3,048 $163
2020 $1,970 $473 $161–$1,480 $114
2021 $504 $677 $233–$1,827 $132
2022 $1,074 $978 $333–$2,724 $149
2023 $2,257 $1,136 $382–$2,986 $160
2024 $3,934 $1,181 $395–$3,326 $164
2025 $1,747 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $6,812 7 payments
  2. Edwards Lifesciences Corporation $3,791 73 payments
  3. Abbott Laboratories $2,363 41 payments
  4. Boston Scientific Corporation $1,862 70 payments
  5. Penumbra, Inc. $1,133 15 payments
  6. Abiomed $1,016 16 payments
  7. Cardiovascular Systems Inc. $803 23 payments
  8. Shockwave Medical, Inc $367 2 payments
  9. AstraZeneca Pharmaceuticals LP $204 4 payments
  10. Amgen Inc. $157 6 payments
  11. Other $1,009 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,989 281 payments
  2. Grant $6,500 1 payment
  3. Travel and Lodging $3,029 14 payments
Products named General payments · program years 2019–2025
  1. Resolute $6,559 2 payments
  2. MITRACLIP Vascular $1,061 7 payments
  3. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,058 9 payments
  4. Indigo System $936 11 payments
  5. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $687 36 payments
  6. Impella $674 11 payments
  7. Peripheral Orbital Atherectomy System $580 18 payments
  8. Coronary Orbital Atherectomy System $426 12 payments
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $367 2 payments
  10. MitraClip Structural Heart $366 7 payments
  11. Other $4,687 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

3,783

Median for Interventional Cardiology: 2,236

Drug cost

$487,793

Median for Interventional Cardiology: $380,412

Branded share of claims

32.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 278 $191,844
Repatha Sureclick Evolocumab Brand 42 $60,965
Entresto Sacubitril/Valsartan Brand 77 $51,359
Jardiance Empagliflozin Brand 60 $47,903
Farxiga Dapagliflozin Propanediol Brand 40 $35,467
Praluent Pen Alirocumab Brand 22 $31,225
Vascepa Icosapent Ethyl Brand 42 $19,146
Brilinta Ticagrelor Brand 29 $13,260
Xarelto Rivaroxaban Brand 18 $11,375
Atorvastatin Calcium Generic 644 $4,472

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$159,766

Medicare's payments for the services billed

Medicare patients

649

Average age 74

Services billed

2,316

318 women, 331 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 54%
Diabetes 44%
Atrial fibrillation 42%
Heart failure 40%
COPD 33%
Chronic kidney disease 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $97
$97 40 —
WAINUA
  • AstraZeneca Pharmaceuticals LP $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

296 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record